Azathioprine

Related products

• 

  Psoriatic arthritis (PsA) , Crohn's disease

  Utec monoclonal antibody

  【Product name】Stelara

  [English common name]Ustekinumab

  [Chinese common name]Utec monoclonal antibody

  [English name]

  [Chinese other name]

  [Indications] Stelara is a drug used to treat the following diseases:
  Moderate to severe plaque psoriasis (a disease that causes red, scaly plaque in the skin). It is used in adults and children over the age of 12, and its condition is unresponsive or cannot be treated with other systemic (systemic) psoriasis, such as cyclosporine, methotrexate or PUVA (psoralen UV A). PUVA is a treatment in which a patient receives a drug containing a compound called "psoralen" prior to exposure to ultraviolet light.
  Activity in adultsPsoriatic arthritis(Inflammation of the joints associated with psoriasis), when the condition is not adequately responsive to other treatments, is called anti-rheumatic drugs (DMARDs) that improve the disease. Stelara can be used alone or in combination with methotrexate (DMARD); moderate to severe activity in adultsCrohn's disease(a disease that causes intestinal inflammation), whose condition is poorly responsive to other Crohn's disease treatments or is unacceptable for such treatment.

  [Usage and Dosage] Adults aged 18 years and older started treatment with a loading dose of 320 mg delivered to two 2 ml, subcutaneously 160 mg on the same day at two different locations. Continue to use a weekly injection of 160 mg as a single, 2 ml, subcutaneously administered dose. Don't give ARCALYST more often than once a week. Pediatric patients are 12 to 17 years old: the starting dose for treatment is 4.4 mg/kg, up to 320 mg, delivered with one or two subcutaneous injections, with a maximum single injection volume of 2 mL. Continue to administer a weekly injection of 2.2 mg/kg, up to 160 mg, as a single subcutaneous injection, up to 2 ml. If the initial dose given is two injections, they should be on the same day at two different locations. Don't give ARCALYST more often than once a week.

  [Storage] Store in the refrigerator (2 ° C – 8 ° C). Do not freeze. Keep the vial in an outer carton to prevent light from shining.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Behcet disease

  Thalidomide

  【Product name】Thalomid

  [English common name]Thalidomide

  [Chinese common name]Thalidomide

  [English name]2-phthalimidoglutarimide

  [Chinese other name]Thalidomide

  [indications]
  Thalidomide capsule: a dermatological treatment. Used to control neoplastic leprosy.
  Thalidomide tablets: used to control neoplastic leprosy.

  【Dosage】
  Thalidomide capsules: 25-50mg (1-2 tablets) once a day, 100-200mg (4-8 tablets) a day or as directed by your doctor.
  Thalidomide tablets: oral. 25-50mg (1-2 tablets), 100-200mg (4-8 tablets) a day, or as directed by your doctor.

  [Storage]
  Thalidomide capsules: shading, sealed storage.
  Thalidomide tablets: shading, sealed and preserved.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Crohn's disease

  5-aminosalicylic acid

  【Product name】CANASA

  [English common name]5-Aminosalicylic acid

  [Chinese common name]5-aminosalicylic acid

  [English name]5-ASA; 5-Amino salicylic acidl, Mesalazine

  [Chinese other name]5-amino-2-hydroxybenzoic acid, mesalazine

  [Indications] For the treatment of ulcerative colitis, Crohn's disease; suppositories for the treatment of ulcerative proctitis, can also be combined with mesalazine tablets.

  [Usage and Dosage] Oral: Adult, ulcerative colitis (acute attack): 4 times a day, 1g each time; maintenance treatment, 3 times a day, 0.5g each time.
  Crohn's disease: 4 times a day, 1g each time. For children over 2 years old, take 20-30mg per kilogram of body weight per day, in divided doses.
  Suppository: Adult, 1-2 times a day, 1 suppository each time. Children over the age of two, follow the doctor's advice.

  [Storage] The tablets should be stored at room temperature (15-25 °C) and should not be taken after the expiration date. Suppositories should be stored at room temperature (15-25 °C) in the original package and should not be used after the expiration date.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Crohn's disease , Behcet disease

  Infliximab

  【Product name】REMICADE, Remicade

  [English common name]Infliximab

  [Chinese common name]Infliximab

  [English name]

  [Chinese other name]

  [indications]
  Rheumatoid Arthritis
  This product is a disease-control anti-rheumatic drug. For patients with moderate to severe active rheumatoid arthritis, this product can be used in combination with methotrexate:
  · Reduce symptoms and signs;
  · Improve physical function and prevent disability in patients.
  Crohn's disease
  For patients with moderate to severe active Crohn's disease who are not well received by traditional treatment, this product can be used for:
  · Reduce symptoms and signs;
  · Achieve and maintain clinical efficacy;
  · Promote mucosal healing;
  · Improve the quality of life;
  · Reduce the amount of corticosteroids or stop using corticosteroids.
  Tracheal Crohn's disease
  For patients with fistile Crohn's disease, this product can be used for:
  Reduce the number of intestinal-cutaneous fistulas and rectal-vaginal fistulas to promote and maintain fistula healing;
  · Reduce symptoms and signs;
  · Improve the quality of life.
  Ankylosing spondylitis
  For patients with active ankylosing spondylitis, this product can be used for:
  · Alleviate symptoms and signs, including increasing the range of activity;
  · Improve physical function;
  · Improve the quality of life.
  psoriasis
  For patients with psoriasis, this product can be used for:
  Adult patients with chronic severe plaque psoriasis who require systemic treatment and are ineffective, contraindicated or tolerant to other systems such as cyclosporine, methotrexate or photochemotherapy. This product is intended for use only in patients who are treated under close supervision by a physician and regularly followed up by a physician.

  【Dosage】
  Usage: intravenous infusion.
  Rheumatoid Arthritis
  The product was administered 3 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. This product should be combined with methotrexate. For patients with poor efficacy, consider adjusting the dose to 10 mg/kg and/or adjusting the medication interval to 4 weeks.
  Moderate and severe active Crohn's disease, fistula Crohn's disease
  The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. For patients with poor efficacy, consider adjusting the dose to 10 mg/kg.
  Ankylosing spondylitis
  The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 6 weeks after the second week and the sixth week after the first administration and thereafter.
  User guides
  Sterility should be performed.
  1. Calculate the dosage and determine the number of bottles used in this product: This product contains 100mg of infliximab per bottle, and calculate the total amount of the solution to be prepared.
  2. Dissolve each bottle of medicine with 10 ml of sterile water for injection using a syringe equipped with a 21 gauge (0.8 mm) or smaller needle: remove the flip of the vial, wipe the top of the vial with a medical alcohol swab, and insert the syringe needle into the vial Cover, inject sterile water for injection. If the vacuum in the vial has been destroyed, the bottle cannot be used. Gently rotate the vial to dissolve the powder. Avoid shaking for a long time or with force. Do not oscillate. Foam may appear during the dissolution of the drug. After 5 minutes of storage, the solution should be colorless or light yellow, and the milk is white. Since infliximab is a protein, there may be some translucent particles in the solution. If opaque particles, discoloration or other substances appear in the solution, they cannot be used any more.
  3. Dilute the sterile aqueous solution of this product to 250 ml with 0.9% sodium chloride injection: withdraw the same amount of liquid from the 250 ml 0.9% sodium chloride injection bottle or bag as the sterile injectable aqueous solution of this product. The sterile aqueous solution for injection of this product is completely injected into the infusion bottle or bag and gently mixed.
  4. The infusion time should not be less than 2 hours: the infusion set should be equipped with a built-in, sterile, pyrogen-free, low protein binding filter (pore size ≤ 1.2 μm). Unused infusions should not be stored for further use.
  5. The physical and biochemical compatibility studies of this product in combination with other drugs have not been carried out, and this product should not be infused simultaneously with other drugs.
  Products administered parenterally should be visually inspected for the presence of particulate matter or discoloration prior to administration. If opaque particles, discoloration, or other foreign matter are found, the drug may not be used.
  Plaque psoriasis
  The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. If the patient does not respond after week 14 (ie, after 4 doses), the product should not be treated.
  Psoriasis patients re-administered
  Patients with psoriasis have limited experience with a single administration after 20 weeks, suggesting a reduction in the effectiveness of the product compared to the initial induction therapy and an increase in mild to moderate infusion response.
  After relapse of the disease, limited experience with repeated induction therapy showed an increase in infusion response (including severe reactions) compared to 8-week maintenance therapy.
  If treatment interruption is maintained, it is not recommended to initiate induction therapy again and should be re-administered according to maintenance therapy.

  [Storage]Store at 2-8 °C in the dark.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.